Find out how NAMs are influencing safety assessments and decision-making in the pharmaceutical industry ahead of 2026.

Pawankumar Suresh enhances early-stage drug research processes, ensuring regulatory compliance through effective systems and vendor governance.

Pfizer scrapped its own obesity drug candidate, Danuglipron, in early 2025, citing risks of liver enzyme elevations. ・The ...

The collaboration marks a turning point in AI-driven drug design and trial forecasting, de-risking the drug development ...

AI and machine learning are revolutionizing drug discovery, development, and lifecycle management, addressing industry ...

The pharmaceutical industry is experiencing its own “DeepSeek moment,” according to science writer Hiya Jain. Just as the upstart AI breakthrough caught Silicon Valley off-guard, China is emerging as ...

Altasciences, a fully integrated drug development solution company, and VoxCell BioInnovation (“VoxCell”), a leader in 3D bioprinting and human-like tissue modeling, are pleased to announce a ...

Despite new methodologies and flexible regulatory pathways, CNS biopharmaceuticals still face significant safety assessment ...

This episode of the Pharmaron DMPK Insights Podcast Series sees Simon Taylor (Vice President of Drug Discovery at Pharmaron) and Dr. Emile Chen (former Director of Modeling and Translational Biology ...

Recent Trends and Patient Outcomes of Phase I Trials: A Single-Institution Experience in the Era of New Therapeutic Agents This study reviewed all industry-sponsored phase I clinical trial protocols ...